iCasp9M28z T cell infusion / Memorial Sloan-Kettering Cancer Center, Bellicum - LARVOL DELTA

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin (clinicaltrials.gov) - P1/2 | N=113 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2024 ➔ Apr 2025 | Trial primary completion date: Apr 2024 ➔ Apr 2025

Trial completion date • Trial primary completion date • Breast Cancer • Lung Cancer • Malignant Pleural Mesothelioma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Respiratory Diseases • Solid Tumor • MSLN • PD-L1

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin (clinicaltrials.gov) - P1/2 | N=113 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2023 ➔ Apr 2024 | Trial primary completion date: Apr 2023 ➔ Apr 2024

Trial completion date • Trial primary completion date • Breast Cancer • Lung Cancer • Malignant Pleural Mesothelioma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Respiratory Diseases • Solid Tumor • MSLN • PD-L1

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin (clinicaltrials.gov) - P1/2; N=113; Active, not recruiting; Sponsor: Memorial Sloan Kettering Cancer Center; Recruiting ➔ Active, not recruiting; N=179 ➔ 113

Clinical • Enrollment change • Enrollment closed • Breast Cancer • Lung Cancer • Malignant Pleural Mesothelioma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Respiratory Diseases • Solid Tumor • MSLN • PD-L1

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin (clinicaltrials.gov) - P1/2; N=179; Recruiting; Sponsor: Memorial Sloan Kettering Cancer Center; Trial completion date: Apr 2021 ➔ Apr 2023; Trial primary completion date: Apr 2021 ➔ Apr 2023

Clinical • Trial completion date • Trial primary completion date • Breast Cancer • Lung Cancer • Malignant Pleural Mesothelioma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Respiratory Diseases • Solid Tumor • MSLN • PD-L1

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin (clinicaltrials.gov) - P1/2; N=179; Recruiting; Sponsor: Memorial Sloan Kettering Cancer Center; Phase classification: P1 ➔ P1/2; N=66 ➔ 179

Clinical • Enrollment change • Phase classification • Breast Cancer • Lung Cancer • Malignant Pleural Mesothelioma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Respiratory Diseases • Solid Tumor • Thoracic Cancer • MSLN • PD-L1

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin (clinicaltrials.gov) - P1; N=66; Recruiting; Sponsor: Memorial Sloan Kettering Cancer Center; Trial completion date: Apr 2020 ➔ Apr 2021; Trial primary completion date: Apr 2020 ➔ Apr 2021

Clinical • Trial completion date • Trial primary completion date • Breast Cancer • Lung Cancer • Malignant Pleural Mesothelioma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Respiratory Diseases • Solid Tumor • Thoracic Cancer • MSLN • PD-L1

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin (clinicaltrials.gov) - P1; N=24; Recruiting; Sponsor: Memorial Sloan Kettering Cancer Center; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Breast Cancer • Lung Cancer • Malignant Pleural Mesothelioma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Respiratory Diseases • Solid Tumor • Thoracic Cancer • MSLN • PD-L1

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin (clinicaltrials.gov) - P1; N=48; Recruiting; Sponsor: Memorial Sloan Kettering Cancer Center; N=36 ➔ 48

Clinical • Enrollment change • Breast Cancer • Lung Cancer • Malignant Pleural Mesothelioma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Respiratory Diseases • Solid Tumor • Thoracic Cancer • MSLN • PD-L1

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin (clinicaltrials.gov) - P1; N=66; Recruiting; Sponsor: Memorial Sloan Kettering Cancer Center; N=48 ➔ 66

Clinical • Enrollment change • Breast Cancer • Lung Cancer • Malignant Pleural Mesothelioma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Respiratory Diseases • Solid Tumor • Thoracic Cancer • MSLN • PD-L1

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin (clinicaltrials.gov) - P1; N=48; Recruiting; Sponsor: Memorial Sloan Kettering Cancer Center; Trial completion date: Apr 2019 ➔ Apr 2020; Trial primary completion date: Apr 2019 ➔ Apr 2020

Clinical • Trial completion date • Trial primary completion date • Breast Cancer • Lung Cancer • Malignant Pleural Mesothelioma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Respiratory Diseases • Solid Tumor • Thoracic Cancer • MSLN • PD-L1

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin (clinicaltrials.gov) - P1; N=36; Recruiting; Sponsor: Memorial Sloan Kettering Cancer Center; N=24 ➔ 36; Trial completion date: Apr 2018 ➔ Apr 2019; Trial primary completion date: Apr 2018 ➔ Apr 2019

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Breast Cancer • Lung Cancer • Malignant Pleural Mesothelioma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Respiratory Diseases • Solid Tumor • Thoracic Cancer • MSLN • PD-L1

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin (clinicaltrials.gov) - P1; N=24; Not yet recruiting; Sponsor: Memorial Sloan Kettering Cancer Center

Clinical • New P1 trial • Breast Cancer • Lung Cancer • Malignant Pleural Mesothelioma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Respiratory Diseases • Solid Tumor • Thoracic Cancer • MSLN • PD-L1